Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The acquisition will strengthen the overall company’s position as leading global CRO services partner
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated
